Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 716 across all filing types
Latest filing 2026-05-28 Audit Report / Informat…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Raport z oceny SoW 2025
Audit Report / Information Classification · 95% confidence The document is an independent auditor’s (PwC) attestation report providing an opinion on the completeness and compliance of the Company’s Remuneration Report (“Sprawozdanie o wynagrodzeniach”) for the year ended December 31, 2025. It contains auditor responsibilities, applicable standards (KSUA 3000 (Z)), scope of work, and an audit opinion. This is a standalone audit/attestation report rather than a full annual or interim financial statement, and thus it fits the Audit Report / Information category. FY 2025
2026-05-28 Polish
Sprawozdanie o wynagrodzeniach 2025
Remuneration Information Classification · 95% confidence The document is a detailed ‘sprawozdanie o wynagrodzeniach’ (remuneration report) for members of the Management Board (Zarząd) and Supervisory Board (Rada Nadzorcza) of Celon Pharma S.A. for the 2025 period. It outlines compensation policies, fixed and variable pay, benefits, and compliance with the remuneration policy. This matches the definition of a standalone Remuneration Information filing (Code: DEF 14A).
2026-05-28 Polish
Sprawozdanie RN 2025
Governance Information Classification · 90% confidence The document is titled “Sprawozdanie Rady Nadzorczej” (Supervisory Board Report) of Celon Pharma S.A. for the 2025 fiscal year and includes detailed governance-related content: composition of the Supervisory Board, committees, evaluation of the financial statements, internal controls, compliance with corporate governance practices, and recommendations to the General Meeting. It is not the full Annual Report (no comprehensive management discussion & analysis with complete financial exhibits), nor an earnings release or proxy statement, nor an audit report per se. It is a governance report outlining board structure and oversight activities, which corresponds to the Governance Information category (CGR).
2026-05-28 Polish
Projekty uchwał
AGM Information Classification · 92% confidence The document consists of detailed “Projekt uchwał” (draft resolutions) to be tabled at the Ordinary General Meeting of Celon Pharma S.A. on June 24, 2026. It includes proposals for electing meeting officers, approving financial statements, granting discharge to management, appointing supervisory board members, and more—all of which are materials prepared for and presented at the AGM. This clearly matches the definition of AGM Information (materials shared during an Annual General Meeting).
2026-05-28 Polish
Ogłoszenie o zwołaniu WZA
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice by the management board convening the Ordinary General Meeting (AGM) of shareholders, including agenda items, registration details, shareholders’ procedural rights, and how to propose resolutions and vote. This is not the AGM materials delivered at the meeting, nor is it a simple regulatory announcement; it corresponds to a proxy/information statement sent to shareholders to inform them of the meeting and solicit their votes. Therefore, it best fits the Proxy Solicitation & Information Statement category.
2026-05-28 Polish
Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia Celon Pharma S.A. na dzień 24 czerwca 2026 r. wraz z projektami uchwał - Content (PL)
Proxy Solicitation & Information Statement Classification · 96% confidence The document is a formal convocation notice for the Ordinary General Meeting of Shareholders (Zwyczajne Walne Zgromadzenie) of Celon Pharma S.A., detailing the agenda, draft resolutions, and related attachments sent to shareholders to inform them and solicit their votes. This matches the definition of a Proxy Solicitation & Information Statement.
2026-05-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.